Debbie Dickerson
Impact in
- Infectious Diseases top 5%
- COVID-19 Clinical Research Studies
- SARS-CoV-2 and COVID-19 Research
- SARS-CoV-2 detection and testing
- Neurology top 5%
- Long-Term Effects of COVID-19
Papers in
-
- Epilepsy research and treatment 3
-
- SARS-CoV-2 and COVID-19 Research 2
- Partner nations
- United KingdomAustraliaNetherlands
In The Last Decade
Debbie Dickerson
8 papers receiving 1.2k citations
Debbie Dickerson's Hit Papers
Peers
Comparison fields: 5 of 94
- Infectious Diseases 728
- Neurology 252
- Internal Medicine 54
- Obstetrics and Gynecology 69
- Critical Care and Intensive Care Medicine 34
Countries citing papers authored by Debbie Dickerson
This map shows the geographic impact of Debbie Dickerson's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Debbie Dickerson with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Debbie Dickerson more than expected).
Fields of papers citing papers by Debbie Dickerson
This network shows the impact of papers produced by Debbie Dickerson. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Debbie Dickerson. The network helps show where Debbie Dickerson may publish in the future.
No co-authors to show.
All Works
| # | Work | ||
|---|---|---|---|
| 1 | Convalescent plasma in patients admitted to hospital with COVID-19 (RECOVERY): a randomised controlled, open-label, platform trial Hit paper breakdown → | 2021 | 381 |
| 2 | Casirivimab and imdevimab in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial Hit paper breakdown → | 2022 | 282 |
| 3 | Baricitinib in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial and updated meta-analysis Hit paper breakdown → | 2022 | 230 |
| 4 | Aspirin in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial Hit paper breakdown → | 2021 | 211 |
| 5 | 2023 | 83 | |
| 6 | 2023 | 9 | |
| 7 | 2022 | 6 | |
| 8 | 2023 | 6 |
About Debbie Dickerson
Debbie Dickerson is a scholar working on Psychiatry and Mental health, Infectious Diseases, Genetics, Rheumatology and Pediatrics, Perinatology and Child Health, having authored 8 papers that have together received 1.2k indexed citations. Recurring topics across this work include Epilepsy research and treatment (3 papers), SARS-CoV-2 and COVID-19 Research (2 papers), Genetics and Neurodevelopmental Disorders (2 papers), Functional Brain Connectivity Studies (1 paper), EEG and Brain-Computer Interfaces (1 paper), Glycogen Storage Diseases and Myoclonus (1 paper) and Pharmacological Effects and Toxicity Studies (1 paper). The work is most often cited by research in Infectious Diseases (728 citations), Neurology (252 citations), Internal Medicine (54 citations), Obstetrics and Gynecology (69 citations) and Critical Care and Intensive Care Medicine (34 citations). Debbie Dickerson has collaborated with scholars based in United Kingdom, Australia and Netherlands. Their work appears in journals such as The Lancet, Brain Communications and npj Genomic Medicine.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.